Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline
Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N, Stedman M, MIDAS Investigators
Alzheimer's & dementia : the journal of the Alzheimer's Association · 355 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2010-05-01 · Alzheimers Dement · vol. 6 · número 6 · págs. 456–464
- Editorial
- Wiley
- Citado
- 579 citas · más que el 100% de estudios similares · 28.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 43 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Dementia and Cognitive Impairment Research · Alzheimer's disease research and treatments
- Palabras clave
- docosahexaenoic acid, omega-3 supplementation
- MeSH
- humans, dementia, memory disorders, docosahexaenoic acids, nootropic agents, double-blind method, cognition disorders, aging, aged, middle aged, female, male, learning disabilities
9 autores
- Karin Yurko‐Mauro · autor de correspondencia
- Deanna McCarthy
- Dror Rom
- Edward B. Nelson
- Alan S. Ryan
- Andrew D. Blackwell🇬🇧Cambridge Cognition (United Kingdom)
- Norman Salem
- Mary Stedman🇺🇸Stedman Clinical Trials
- MIDAS Investigators
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age-related cognitive decline (ARCD) have not been fully examined.
Objective
Determine effects of DHA administration on improving cognitive functions in healthy older adults with ARCD.
Methods
Randomized, double-blind, placebo-controlled, clinical study was conducted at 19 U.S. clinical sites. A total of 485 healthy subjects, aged ≥55 with Mini-Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score ≥1 standard deviation below younger adults, were randomly assigned to 900 mg/d of DHA orally or matching placebo for 24 weeks. The primary outcome was the CANTAB Paired Associate Learning (PAL), a visuospatial learning and episodic memory test.
Results
Intention-to-treat analysis demonstrated significantly fewer PAL six pattern errors with DHA versus placebo at 24 weeks (difference score, -1.63 ± 0.76 [-3.1, -0.14, 95% CI], P = .03). DHA supplementation was also associated with improved immediate and delayed Verbal Recognition Memory scores (P < .02), but not working memory or executive function tests. Plasma DHA levels doubled and correlated with improved PAL scores (P < .02) in the DHA group. DHA was well tolerated with no reported treatment-related serious adverse events.
Conclusions
Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging.
Trial registration
Clinicaltrials.gov, Identifier: NCT0027813.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.